Formulation and Evaluation of an Emulgel Containing Piroxicam and Lidocaine for the Treatment of Musculoskeletal Disorders

Musculoskeletal disorders (MSDs), such as arthritis, sprains, and muscle strains, are widespread conditions that cause pain, inflammation, and limited mobility. Long-term use of oral medications for these conditions can result in systemic side effects, including gastrointestinal irritation and liver toxicity. To overcome these issues, a topical emulgel combining Piroxicam and Lidocaine was developed to provide localized dual-action therapy. The formulation was prepared using Carbopol 940 as the gelling agent, with Span 80 and Tween 80 as emulsifiers, and was evaluated for physicochemical properties, including pH, viscosity, Spreadability, drug content, and stability. The optimized emulgel was stable, non-irritant, and demonstrated suitable physicochemical characteristics. The combination of Piroxicam and Lidocaine provided synergistic effects, with Piroxicam reducing inflammation and Lidocaine offering rapid pain relief. This emulgel offers a safe and patient-friendly approach for managing MSDs, delivering effective localized therapy while minimizing systemic exposure.